Latest Commentary




Here are 3 examples in the biotech field where I think you can make a case that current pricing is cheap for impressive Australian companies with global prospects.

Full Article >

In our “HOT” stock column, Michael Gable, Managing Director of Fairmont Equities, says that at current levels, the Big Australian is a buy, and he expects its share price to meander back up toward..

Full Article >

Within the broad “tech” label, here are two stocks I think have proprietary services that are growing their businesses very nicely — though neither is yet profitable.

Full Article >